This commentary examines methodological considerations pertaining to treatment studies of postpartum depression (PPD). A prominent consideration is whether PPD is a temporal subtype of major depressive disorder (MDD) or a distinct mood disorder. We propose that PPD should be appreciated as a heterogeneous depressive disorder embedded within a unique biopsychosocial context. A nuanced approach is essential for the design and implementation of clinical trials that are scientifically rigorous, clinically meaningful, and generalizable to the women most likely to benefit from emerging therapies.
Diagnosis and Heterogeneity
One of the central questions facing investigators is deceptively simple: What exactly constitutes PPD? PPD is characterized by its timing as a depressive episode following childbirth. There are debates about whether PPD is a biologically distinct disorder caused by neurosteroid fluctuations or a more heterogeneous manifestation of MDD with postpartum occurrence. We propose that PPD represents a heterogeneous disorder for whom a subset of patients are specifically triggered by hormonal changes1 and that it is often oversimplified and unappreciated for its nuances. PPD is not experienced universally despite the normal physiological changes subsequent to childbirth, underscoring differential vulnerability. PPD may capture stress-precipitated, recurrent, or index episodes of MDD. Differential diagnoses include postpartum index episodes of bipolar depression, anxiety disorders with secondary depressive symptoms, obsessive-compulsive disorder, or combinations of these conditions.2–4 PPD subtypes have not been thus far differentiated by etiology, and there is no clinical or research standard of how to phenotype PPD. However, heterogeneity matters for the assessment of candidate interventions and design of clinical trials, which ultimately affect how treatments are selected by patients and clinicians.
DSM-5 does not contain a specific PPD diagnosis. The working definition for PPD in clinical registration trials has been derived from the DSM-5 diagnosis of MDD as a major depressive episode with a perinatal specifier—onset in pregnancy or within 4 weeks of childbirth, although clinicians, patients, advocates, and researchers often use different definitions.5
Considering heterogeneity, clinical trials should strive for the capture of greater phenotypic precision, allowing investigators to understand not simply whether a treatment works, but in whom it works best. This precision medicine approach is going to be essential for our field. For example, it is unknown if PPD responds differently to treatments whether it had antenatal or postpartum onset, or if treatment initiation is at 2 months vs 12 months postpartum. Notably, clinical presentation may differ widely, with many women with PPD experiencing severe anxiety, obsessive-compulsive symptoms, irritability, insomnia, anger, overwhelming guilt, and difficulties with maternal-infant bonding.6 Careful characterization of study populations is essential for interpreting trial results and improving generalizability, as well as for the development of tailored interventions for subtypes and other postpartum psychiatric disorders. Duration of illness, previous treatment exposure, treatment resistance, and psychiatric history may all influence response to novel interventions.
State of Drug Development and Regulatory Considerations
Drug development for PPD has evolved rapidly, now catalyzed by a recognized regulatory indication of PPD. It is unclear whether interventions under study for PPD will work uniquely for PPD or rather work more generally as antidepressants. Notably, the regulatory pathway differs for approval of agents for PPD in comparison to MDD. PPD trials are generally much shorter in duration, with fewer requirements for longer term follow-up, perhaps reflecting the common belief that PPD is a homogeneous and time-limited disorder. Presumably, this makes trials in PPD less costly than those in MDD for potential regulatory approval, making PPD an attractive target indication. For example, divergent regulatory expectations—together with the fact that the same molecule, zuranolone, earned US Food and Drug Administration (FDA) approval for PPD yet received a Complete Response Letter for MDD—make the question of whether PPD is truly distinct from MDD not merely academic but directly consequential for how trials are designed and interpreted.
Since thus far PPD registration trials have been relatively short and without long-term follow-up, clinicians increasingly seek guidance regarding treatment after brief therapeutic courses, including questions about maintenance therapy, retreatment following depressive relapse, compatibility with breastfeeding, risks of exposure in subsequent pregnancies, and use in other postpartum psychiatric disorders. Addressing these questions deserves additional studies that closely reflect the clinical realities encountered by patients and clinicians.
The Unique Clinical Context of PPD
Without dispute, untreated postpartum and maternal depression carry demonstrated harms for both mother and child,7 and safe, efficacious, and rapidly acting treatments are critical to the welfare of the mother and mother-baby dyad. PPD occurs during a major life transition as a mother bonds with and cares for an infant, often while breastfeeding, and this context frames every methodological aspect of study conduct and interpretation. Clinical trials in psychiatry have long struggled with challenges related to high placebo response rates,8 and it is possible that postpartum participants may be especially influenced by trial design factors that affect placebo response. For example, inpatient PPD trials that provide empathic support and uninterrupted sleep may inflate placebo responses. In addition, PPD introduces additional complexities to clinical trial design and interpretation. The postpartum is characterized by hormonal/neurosteroid transitions, disrupted sleep, infant caregiving responsibilities, breastfeeding decisions, evolving family dynamics, reproductive planning, and substantial psychosocial stressors. These contextual factors influence symptom presentation and also factor into the precision of diagnosis, recruitment, retention, safety monitoring, treatment selection, and interpretation of outcomes.
Outcome Measures: Beyond Symptom Reduction
Most contemporary PPD trials rely upon clinician-rated scales such as the Montgomery-Asberg Depression Rating Scale or the Hamilton Depression Rating Scale as primary efficacy end points. While these instruments have demonstrated reliability across studies of MDD, their application to postpartum populations warrants careful consideration.
Many symptoms that dominate the postpartum experience—including anxiety, intrusive thoughts, maternal guilt, impaired confidence, sleep disruption related to infant care, and difficulties with maternal-infant bonding—may not be adequately captured and contextualized by conventional depression rating scales.
Self-report measures developed to screen for PPD specifically such as the Edinburgh Postnatal Depression Scale are often utilized but are usually not accepted as primary end points because they are not clinician-rated or validated as study outcome measures. Studies may benefit from incorporating validated self-rating outcome scales, evaluation of a broader range of postpartum symptoms, and additional functional outcomes.
Recruitment, Ecological Validity, and Generalizability
Recruitment remains among the greatest practical challenges in PPD trials. Postpartum women often have limited time, competing caregiving responsibilities, disrupted sleep, and transportation and childcare barriers. Universal PPD screening has expanded substantially, yet screening does not necessarily translate into referrals to clinical care or research studies.9 Careful diagnostic assessment remains essential to ensure that the appropriate patients enter PPD studies.10 Traditional randomized clinical trials maximize internal validity by limiting variability. However, strict eligibility criteria may substantially reduce generalizability because many women with PPD present with psychiatric comorbidity, use of ongoing psychotherapy and/or concurrent antidepressant treatment, complex medical conditions, or significant psychosocial adversity. Future investigations should seek an appropriate balance between scientific control and clinical relevance through pragmatic trial designs, broader inclusion criteria, and carefully planned subgroup analyses.
Placebo Response: A Methodologic Challenge
High placebo response rates may obscure the ability to detect the efficacy of a treatment and are increasingly common throughout psychiatric drug development. Certain elements of clinical trials may raise placebo response rates, perhaps especially pertinent to postpartum women. Factors include regular contact with compassionate clinicians, repeated assessments, careful monitoring, and opportunities to discuss their experiences openly. These nonspecific therapeutic factors may themselves contribute meaningfully to clinical improvement. Better understanding these nonspecific therapeutic effects may ultimately improve both clinical trial design and routine clinical care. Clinical trial methodologies aimed at reducing the placebo response, such as the sequential parallel comparison design (SPCD), serve to mitigate the risk of failed trials.11
Breastfeeding and Women of Childbearing Potential in Clinical Trials
Breastfeeding represents one of the most distinctive methodological challenges in PPD research. Decisions regarding infant feeding are influenced by maternal preferences, cultural expectations, infant health, and public health recommendations. Many trials require women to interrupt or discontinue breastfeeding because of limited safety data, creating a significant barrier to participation and potentially reducing generalizability. Studies should incorporate lactation pharmacology and pharmacokinetic investigations whenever feasible.
Earlier collection of breastfeeding safety data could facilitate broader participation and better inform clinical decision-making after regulatory approval.
The postpartum period also introduces unique reproductive safety considerations. Ovulation may resume within weeks after delivery, and unintended pregnancy may occur during trials.12–14 Pregnancy testing and contraceptive counseling become important methodological considerations. Postmarketing pharmacovigilance, especially pregnancy registries, has been recommended by regulatory agencies such as the US FDA for medications that are used for disorders that affect women of childbearing age.15
Safety Monitoring: Suicidality, Bipolar Disorder, and Postpartum Psychosis
Comprehensive safety assessment is paramount. Suicide remains an important contributor to maternal mortality, and investigators must incorporate systematic assessment of suicidal ideation throughout study participation, along with rigorous safety plans.16–18 Additionally, clinicians must be aware that PPD may represent the first manifestation of bipolar disorder or precede postpartum psychosis.19 Careful screening for previous manic or hypomanic symptoms, for family history of bipolar disorder, and for psychotic symptoms is essential both to protect participants and to improve diagnostic precision. Active monitoring for emergence of mania/hypomania or psychotic symptoms must be integrated into trials for patient safety.
Ethical Considerations in Trial Design
Ethical questions are particularly salient in PPD research considering the well characterized impact of the untreated disorder on the individual and her child(ren). Effective treatments are already available, including psychotherapy, selective serotonin reuptake inhibitors, and zuranolone. Investigators must carefully justify placebo-controlled designs and ensure that women who are not eligible for trial participation receive appropriate clinical referrals and psychoeducation.
Lessons From Recently Approved Therapies
The development of neurosteroid therapies has transformed the field of PPD. Brexanolone and zuranolone studies demonstrated that rapid improvement is achievable, but they also highlighted important unanswered questions. Clinicians now seek guidance regarding durability of response, maintenance treatment, retreatment after relapse, compatibility with breastfeeding, use during pregnancy and prophylactically after subsequent pregnancies, and their broader use in psychiatric disorders outside the postpartum.
From a regulatory standpoint, these approvals also illustrate why PPD trial methodology cannot be considered in isolation from the pathways that govern it. An emerging question is also whether the regulatory pathway for a PPD treatment is easier than one for MDD, and whether it should be so. Both approved neurosteroid agents reached patients through the US Food and Drug Administration’s expedited programs—Breakthrough Therapy designation and Priority Review—on the strength of compact registration programs with primary end points assessed within days to weeks and comparatively brief follow-up. Brexanolone (2019) was the first therapy approved specifically for PPD and requires a 60-hour intravenous infusion under a Risk Evaluation and Mitigation Strategy, whereas zuranolone (2023) is a 14-day oral course, scheduled as a controlled substance. Notably, zuranolone was approved for PPD yet received a Complete Response Letter for MDD—a de facto regulatory statement that the postpartum indication was judged on its own evidentiary footing. Neither agent is currently approved in the European Union, leaving important international evidence gaps and divergent access. These realities argue for building maintenance, retreatment, lactation, and pregnancy-safety questions into prospectively planned postmarketing requirements rather than deferring them or treating them as voluntary.
Conclusion
The next generation of PPD trials should move beyond traditional antidepressant paradigms toward designs that better reflect the realities of women’s lives during the postpartum. By integrating scientific rigor with ecological validity, investigators can generate evidence that is not only suitable for regulatory decision-making but also directly applicable to clinical care.
It is exciting that expedient and efficacious treatment of PPD has become a focus of treatment development. The therapeutic pipeline includes additional neurosteroids, psychedelic compounds and psychoplastogens, neuromodulation, and digital interventions. However, treatment approval for PPD is a milestone, not an end point. A greater understanding of PPD is necessary in order to leverage discoveries to treat a range of postpartum psychiatric illnesses and disorders outside the postpartum. For example, if a treatment approved for PPD is truly not specifically efficacious only for PPD, it seems that investment in studies that would optimize its potential to help the greatest number of patients would be an imperative.
Article Information
Published Online: November 18, 2026. https://doi.org/10.4088/JCP.26com16649
© 2026 Physicians Postgraduate Press, Inc.
J Clin Psychiatry 2026;87(4):26com16649
Submitted: August 6, 2026; accepted August 6, 2026.
To Cite: Freeman MP, Fava M, Pani L. Methodological considerations in clinical trials for postpartum depression: beyond traditional antidepressant trial design.
J Clin Psychiatry 2026;87(4):26com16649.
Author Affiliations: Clinical Trials Network and Institute (CTNI), Massachusetts General Hospital (MGH), Boston, Massachusetts (Freeman, Fava); Department of Psychiatry, Mass General Brigham (Massachusetts General Hospital, Brigham and Women’s Hospital and McLean Hospital), Boston, Massachusetts (Freeman, Fava); Ammon-Pinizzotto Center for Women’s Mental Health, Perinatal and Reproductive Psychiatry, MGH, Boston, Massachusetts (Freeman); Department of Psychiatry and Behavioral ciences, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida (Pani); Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia (UNIMORE), Modena, Italy (Pani).
Corresponding Author: Marlene P. Freeman, MD, Massachusetts General Hospital, Center for Women’s Mental Health, Simches Research Building, Floor 2, 185 Cambridge St, Boston, MA 02114 ([email protected]).
Financial Disclosure: Dr Freeman reports the following financial relationships within the past 36 months (some are not current): As an employee of Massachusetts General Hospital (MGH), Dr Freeman works with the MGH CTNI and MGH Center for Women’s Mental Health, which has had research funding from multiple pharmaceutical companies and National Institute of Mental Health (NIMH). MGH National Pregnancy Registry: Current Sponsors: Alkermes, Inc. (2016-Present); Bristol-Myers Squibb Company (2025-Present); Eisai Inc. (2022-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019–2023, 2024-Present); Supernus Pharmaceuticals (2021-Present). Past Sponsors: Forest/Actavis/Allergan (2016–2018, declined to sponsor: 2018-Present); Aurobindo Pharma (2020–2022, declined to sponsor: 2022-Present); AstraZeneca Pharmaceuticals (2009–2014, declined to sponsor: 2014-Present); AuroMedics Pharma LLC (2021–2022, declined to sponsor: 2022-Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019–2023, declined to sponsor: 2024-Present) ; Ortho-McNeil-Janssen harmaceuticals, Inc (2009–2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009–2011, declined to sponsor: 2012-Present); Sunovion Pharmaceuticals, Inc. (2011–2023, declined to sponsor: 2024-Present); Teva Pharmaceutical Industries Ltd. (2018–2025; declined to sponsor 2025-Present);Dr. Reddy’s Laboratories, Inc. (2023–2025, declined to sponsor 2025-Present). Updated sponsors can be found at https://womensmentalhealth.org/research/pregnancyregistry/. Research through MGH: Sage, National Institute on Aging, NIMH. Consulting through CTNI through MGH (included below). Advisory boards or consulting, Data Safety Committees/Independent Data Safety and Monitoring Committees: Janssen (Johnson& Johnson), Novartis, Neurocrine; Eliem, Sage; Brainify; Everly Health; Tibi Health; Relmada; Beckley Psytech; Brii Biotech; Reunion; Vistagen; Mycomedica. Educational activities (speaking, planning): MGH Psych Academy, WebMD, Medscape, Pri-Med, Postpartum Support International, PRIME, HMP Global, CME Institute. Dr Fava reports the following financial relationships within the past 36 months: research support: Abbvie; Acadia Pharmaceuticals; Aditum Bio Management Company, LLC; Allergan, Alkermes, Inc.; Alto Neuroscience, Inc.; Ancora Bio, Inc.; Angelini S.p.A; Aptinyx; Atai Therapeutics, Inc.; Autobahn Therapeutics, Inc.; Axsome; BioClinica, Inc.; Biogen; BioHaven; BioShin Limited; Centrexion Therapeutics Corporation; Clexio Biosciences, Ltd; Cybin IRL Limited; Damona Pharmaceuticals; Draig Therapeutics Limited; EmbarkNeuro; Eliem Therapeutics LTD; Gate Neurosciences, Inc.; GenOmind, LLC; Gerbera Therapeutics, Inc.; GH Research Ireland Limited; Gilgamesh Pharmaceuticals, Inc.; Janssen Research & Development LLC; Janssen Pharmaceutica NV; Johnson & Johnson; Lundbeck Inc.; Medpace, Inc.; Mind Medicine Inc.; Minerva Neurosciences; NeuraWell Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Novaremed; Neumora Therapeutics, Inc.; Otsuka; Peachtree BioResearch Solutions Inc.; Premiere Research International; Praxis Precision Medicines; Protagenic Therapeutics, Inc.; Relmada Therapeutics Inc.; Seaport Therapeutics, Inc.; Shenox Pharmaceuticals; University of Florida Board of Trustees; Vistagen; WinSanTor, Inc.; Xenon Pharmaceuticals, Inc.; XW Pharma Ltd.; National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); NIMH; and PCORI. Dr. Fava has not done any personal consulting. Any consulting he has done has been on behalf of Massachusetts General Hospital, except for Revival Therapeutics (no longer in existence) and Sensorium Therapeutics. Stock/other financial options: equity holdings: Compellis (no longer in existence); Neuromity; Psy Therapeutics; Revival Therapeutics (no longer in existence); Sensorium Therapeutics. Royalty/patent, other income: Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505); patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven; and patents for pharmacogenomics of Depression Treatment with Folate (US_9546401, US_9540691) licensed to Nestle and for Compound for improving l-arginine bioavailability (US_11,655,210) licensed to DimeRx. Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), Anxiety Symptoms Questionnaire (ASQ), and SAFER; Belvoir; Lippincott, Williams & Wilkins; Wolters Kluwer; World Scientific Publishing Co. Pte.Ltd. All lifetime disclosures can be viewed online by navigating to: https://mghcme.org/maurizio-fava-bio-disclosure/. Dr Pani reports the following financial relationships within the past 36 months: consulting, advisory, or speaking relationships with, or research or other compensation from, AbbVie (USA), Acumen (USA), AiCure (USA), Alexion (Italy), AstraZeneca (Italy), Boehringer Ingelheim International GmbH (Germany), Boston Consulting Group (Switzerland), EDRA-LSWR Publishing (Italy), EnZeta Immunotherapies (USA), GH-Pharma (Ireland), GLG Institute (USA), ImmunoGen (USA), Johnson & Johnson (USA), LB Pharmaceuticals (USA), Magdalena BioSciences (USA), MSD (Italy), Lundbeck (Denmark and Italy), Napo Pharmaceuticals (USA and EU), NetraMark (Canada), Pfizer Global (USA), Relmada Therapeutics (USA), Sanofi-Aventis/Genzyme (France and USA), and Takeda (USA). He holds shares or stock options in EnZeta, Relmada Therapeutics, and NetraMark and has a consultancy relationship with NetraMark Corp. He reports no other financial or non-financial interests relevant to this work.
Funding/Support: None.
Use of AI-Assisted Technologies in the Writing Process: Chat GPT 5.5 was used to convert slides to text from a presentation at the MGH CTNI Conference, July 10, 2026; Trieste, Italy. The slides on which this text is based were made by Dr Freeman without the use of AI.
References (19)
- Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. June 2000;157(6):924–930. PubMed CrossRef
- Fairbrother N, Janssen P, Antony MM, et al. Perinatal anxiety disorder prevalence and incidence. J Affect Disord. 2016;200:148–155. PubMed
- Fairbrother N, Challacombe FL, Collardeau F, et al. Perinatal and postpartum obsessive-compulsive disorder. In: Storch EA, Abramowitz JS, McKay D, eds. Complexities in Obsessive Compulsive and Related Disorders: Advances in Conceptualization and Treatment. Oxford University Press; 2021.
- Masters GA, Hugunin J, Xu L, et al. Prevalence of bipolar disorder in perinatal women: a systematic review and meta-analysis. J Clin Psychiatry. 2022;83(5):21r14045. PubMed CrossRef
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed; 2013. https://doi.org/10.1176/appi.books. 9780890425596
- Beck CT, Indman P. The many faces of postpartum depression. J Obstet Gynecol Neonatal Nurs. 2005;34(5):569–576. PubMed
- Stein A, Pearson RM, Goodman SH, et al. Effects of perinatal mental disorders on the fetus and child. Lancet. 2014;384(9956):1800–1819. PubMed CrossRef
- Fava M. How should we design future mechanistic and/or efficacy clinical trials?. Neuropsychopharmacology. 2024;49(1):197–204. PubMed CrossRef
- Cox EQ, Sowa NA, Meltzer-Brody SE, et al. The perinatal depression treatment cascade: baby steps toward improving outcomes. J Clin Psychiatry. 2016;77(9):1189–1200. PubMed CrossRef
- Freeman MP, Pooley J, Flynn MJ, et al. Guarding the gate: remote structured assessments to enhance enrollment precision in depression trials. J Clin Psychopharmacol. 2017;37(2):176–181. PubMed CrossRef
- Fava M. How should we design future mechanistic and/or efficacy clinical trials?. Neuropsychopharmacology. 2024;49(1):197–204. PubMed CrossRef
- Admon LK, MacCallum-Bridges C, Daw JR. Trends in short interpregnancy interval births in the United States, 2016-2022. Obstet Gynecol. 2025;145(1):82–90. PubMed CrossRef
- Ahrens KA, Thoma ME, Copen CE, et al. Unintended pregnancy and interpregnancy interval by maternal age, National Survey of Family Growth. Contraception. 2018;98(1):52–55. PubMed CrossRef
- Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol. 2011;117(3):657–662. PubMed CrossRef
- US Food and Drug Administration. Postapproval Pregnancy Safety Studies: Guidance for Industry. US Food and Drug Administration; 2026. Accessed August 31, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-pregnancy-safety-studies
- Sit D, Luther J, Buysse D, et al. Suicidal ideation in depressed postpartum women: associations with childhood trauma, sleep disturbance and anxiety. J Psychiatr Res. 2015;66-67:95–104. PubMed CrossRef
- Goldman-Mellor S, Olfson M, Gemmill A, et al. Incidence and risk factors for suicide attempt during pregnancy and the postpartum period. J Clin Psychiatry. 2025;86(2):24m15633. PubMed CrossRef
- Vanderkruik R, Freeman MP, Dunn KA, et al. The challenge of clinical research and suicidality: participant feedback on a safety protocol. J Clin Psychiatry. 2023;84(4):22m14737. PubMed CrossRef
- Cohen LS, Arakelian M, Church TR, et al. The phenomenology of postpartum psychosis: preliminary findings from the Massachusetts General Hospital Postpartum Psychosis Project. Mol Psychiatry. 2025;30(6):2537–2544. PubMed CrossRef
This PDF is free for all visitors!